BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Esbriet pirfenidone regulatory update

Germany's health technology assessment agency said InterMune's Esbriet pirfenidone provides "no additional benefit" compared with best supportive care in patients with idiopathic pulmonary fibrosis (IPF). The Institute for Quality and Efficiency in Health Care (IQWiG) said in its preliminary benefit assessment report that Esbriet provided a "slight additional benefit" on 6 minute walk scores, but the drug did not offer an additional benefit on overall survival, shortness of breath, oxygen use and quality of life. IQWiG...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >